Reduction of oxidative stress marker levels by anti-TNF-α antibody, infliximab, in patients with rheumatoid arthritis

• Published in: Clinical and experimental rheumatology 2008, Vol.26 (1), p.73-80
• Main Authors: KAGEYAMA, Y, TAKAHASHI, M, ICHIKAWA, T, TORIKAI, E, NAGANO, A
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - pharmacology; Antirheumatic Agents - therapeutic use; Arginine - analogs & derivatives; Arginine - analysis; Arginine - blood; Arginine - urine; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - metabolism; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Deoxyguanosine - analogs & derivatives; Deoxyguanosine - urine; Diseases of the osteoarticular system; DNA Damage - drug effects; Female; Glycation End Products, Advanced - metabolism; Humans; Immunomodulators; Inflammatory joint diseases; Infliximab; Isoprostanes - urine; Lipid Peroxidation; Lysine - analogs & derivatives; Lysine - analysis; Lysine - blood; Lysine - urine; Male; Medical sciences; Middle Aged; Oxidative Stress; Pharmacology. Drug treatments; Reactive Oxygen Species
• ISSN: 0392-856X; 1593-098X

The aim of this study was to evaluate the effects of anti-TNF-alpha antibody, infliximab, on oxidative stress markers representing DNA damage, lipid peroxidation, and glycoxidation. Twenty-three RA patients underwent infliximab treatment and were analyzed for 30 weeks. Six patients who experienced side effects and one patient who had a reduced efficacy of infliximab were discontinued the infliximab treatment at 30-54 weeks. Sixteen patients were analyzed for 54 weeks. The levels of serum total, urinary total, and free pentosidine, which is an advanced glycation end-product (AGE), and of urinary 15-Isoprostane F2t and 8-hydroxy-deoxy guanosine (8-OHdG) were determined at baseline and at 14, 30, and 54 weeks after initial treatment with infliximab. Serum total, urinary total, and free pentosidine levels were reduced at 54 weeks after initial infliximab treatment. Urinary 15-Isoprostane F2t and 8-OHdG levels were also reduced at 14, 30, and 54 weeks. Urinary 8-OHdG levels in RA patients correlated with CRP and the Disease Activity Score of 28 joints. In RA patients, infliximab plays an essential role as an anti-oxidative agent against AGE formation, oxidative DNA damage and lipid peroxydation.